Combining and enlarging its knowledge and expertise, Fidia wants to become a partner of excellence in the Joint Care and Wound Care market segments - the fields in which the Company has been active longest - selecting new molecules and/or developing innovative technology platforms for hyaluronic acid (HA).

The company holds an extensive patent portfolio worldwide - over 700 covering HA molecular weight fractions, industrial processes, pharmaceutical formulation/ composition, derivatives, and uses. This makes Fidia unique among its peers: HA extraction from different sources, using in-house developed and patented methods, to obtain HAs with different molecular weights and physico-chemical characteristics.

Fidia is continually working to identify new opportunities and develop an industry-leading pipeline of promising new treatments for specific pathologies in highly challenging areas, with products covered by international patents, that are a vital part of the company's heritage, while encouraging its growth and search for innovation.
Photo Company 2

Over 1.100 patents worldwide
Over 700 patients on hyaluronic acid

Key products in our portfolio include HYALGAN®, HYALUBRIX®, HYALONE®, HYMOVIS®, HYALO4®

Farmaceutici S.p.A.

Find out our Corporate Website:

Go to the website

Fidia’s other websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Middle East product portfolio focalizes primarily on therapeutic areas such as joint healthcare and tissue repair.

Fidia Pharma Middle East is focused on providing consumers with innovative products that offer quality, safety and performance and exploring innovative channel strategies to access customers and consumers, such as healthcare e-commerce.